Metabolic syndrome: Is immunosuppression to blame?

Liver Transplantation

Volumn 17, Issue SUPPL. 3, 2011, Pages

  Watt, Kymberly D ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN INHIBITOR; CORTICOSTEROID; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; IMMUNOSUPPRESSIVE AGENT;

ARTICLE; COMORBIDITY; DIABETES MELLITUS; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; IMMUNOSUPPRESSIVE TREATMENT; LIVER TRANSPLANTATION; METABOLIC SYNDROME X; MORBIDITY; OBESITY; PRIORITY JOURNAL; IMMUNOLOGY; LIVER FAILURE; MORTALITY; REVIEW; RISK FACTOR;

COMORBIDITY; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER FAILURE; LIVER TRANSPLANTATION; METABOLIC SYNDROME X; RISK FACTORS;

EID: 84857150629     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.22386     Document Type: Article

References (33)

1. Poonawala A, Nair SP, Thuluvath PJ. Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: a case-control study. Hepatology 2000;32(pt 1): 689-692.
2. Tellez-Avila FI, Sanchez-Avila F, García-Saenz-de-Sicilia M, Chavez-Tapia NC, Franco-Guzman AM, Lopez-Arce G, et al. Prevalence of metabolic syndrome, obesity and diabetes type 2 in cryptogenic cirrhosis. World J Gastroenterol 2008;14: 4771-4775.
3. Megyesi C, Samols E, Marks V. Glucose tolerance and diabetes in chronic liver disease. Lancet 1967;2: 1051-1056.
4. Bianchi G, Marchesini G, Marzocchi R, Pinna AD, Zoli M. Metabolic syndrome in liver transplantation: relation to etiology and immunosuppression. Liver Transpl 2008; 14: 1648-1654.
5. Laryea M, Watt KD, Molinari M, Walsh MJ, McAlister VC, Marotta PJ, et al. Metabolic syndrome in liver transplant recipients: prevalence and association with major vascular events. Liver Transpl 2007;13: 1109-1114.
6. Laish I, Braun M, Mor E, Sulkes J, Harif Y, Ben Ari Z. Metabolic syndrome in liver transplant recipients: prevalence, risk factors, and association with cardiovascular events. Liver Transpl 2011;17: 15-22.
7. Watt KD, Pedersen RA, Kremers WK, Heimbach JK, Charlton MR. Evolution of causes and risk factors for mortality post-liver transplant: results of the NIDDK long-term follow-up study. Am J Transplant 2010;10: 1420-1427.
8. Johnston SD, Morris JK, Cramb R, Gunson BK, Neuberger J. Cardiovascular morbidity and mortality after orthotopic liver transplantation. Transplantation 2002; 73: 901-906.
9. Barritt AS IV, Dellon ES, Kozlowski T, Gerber DA, Hayashi PH. The influence of nonalcoholic fatty liver disease and its associated comorbidities on liver transplant outcomes. J Clin Gastroenterol 2011;45: 372-378.
10. Wawrzynowicz-Syczewska M, Karpińska E, Jurczyk K, Laurans L, Boroń-Kaczmarska A. Risk factors and dynamics of weight gain in patients after liver transplantation. Ann Transplant 2009;14: 45-50.
11. Richards J, Gunson B, Johnson J, Neuberger J. Weight gain and obesity after liver transplantation. Transpl Int 2005;18: 461-466.
12. Schäcke H, Döcke WD, Asadullah K. Mechanisms involved in the side effects of glucocorticoids. Pharmacol Ther 2002;96: 23-43.
13. Weiler N, Thrun I, Hoppe-Lotichius M, Zimmermann T, Kraemer I, Otto G. Early steroid-free immunosuppression with FK506 after liver transplantation: long-term results of a prospectively randomized double-blinded trial. Transplantation 2010;90: 1562-1566.
14. Lau KK, Tancredi DJ, Perez RV, Butani L. Unusual pattern of dyslipidemia in children receiving steroid minimization immunosuppression after renal transplantation. Clin J Am Soc Nephrol 2010;5: 1506-1512.
15. Goodwin JE, Zhang J, Geller DS. A critical role for vascular smooth muscle in acute glucocorticoid-induced hypertension. J Am Soc Nephrol 2008;19: 1291-1299.
16. Øzbay LA, Smidt K, Mortensen DM, Carstens J, Jørgensen KA, Rungby J. Cyclosporin and tacrolimus impair insulin secretion and transcriptional regulation in INS-1E beta-cells. Br J Pharmacol 2011;162: 136-146.
17. Rabkin JM, Corless CL, Rosen HR, Olyaei AJ. Immunosuppression impact on long-term cardiovascular complications after liver transplantation. Am J Surg 2002;183: 595-599.
18. Perrea DN, Moulakakis KG, Poulakou MV, Vlachos IS, Nikiteas N, Kostakis A. Correlation between lipid abnormalities and immunosuppressive therapy in renal transplant recipients with stable renal function. Int Urol Nephrol 2008;40: 521-527.
19. Roy A, Kneteman N, Lilly L, Marotta P, Peltekian K, Scudamore C, Tchervenkov J. Tacrolimus as intervention in the treatment of hyperlipidemia after liver transplant. Transplantation 2006;82: 494-500.
20. Hulzebos CV, Bijleveld CM, Stellaard F, Kuipers F, Fidler V, Slooff MJ, et al. Cyclosporine A-induced reduction of bile salt synthesis associated with increased plasma lipids in children after liver transplantation. Liver Transpl 2004;10: 872-880.
21. Muñoz SJ. Hyperlipidemia and other coronary risk factors after orthotopic liver transplantation: pathogenesis, diagnosis, and management. Liver Transpl Surg 1995; 1(suppl 1): 29-38.
22. Canzanello VJ, Textor SC, Taler SJ, Wilson DJ, Schwartz L, Wiesner RH, et al. Renal sodium handling with cyclosporine A and FK506 after orthotopic liver transplantation. J Am Soc Nephrol 1995;5: 1910-1917.
23. Vaziri ND, Ni Z, Zhang YP, Ruzics EP, Maleki P, Ding Y. Depressed renal and vascular nitric oxide synthase expression in cyclosporine-induced hypertension. Kidney Int 1998;54: 482-491.
24. Textor SC, Burnett JC Jr, Romero JC, Canzanello VJ, Taler SJ, Wiesner R, et al. Urinary endothelin and renal vasoconstriction with cyclosporine or FK506 after liver transplantation. Kidney Int 1995;47: 1426-1433.
25. Vieira JM Jr, Noronha IL, Malheiros DM, Burdmann EA. Cyclosporine-induced interstitial fibrosis and arteriolar TGF-beta expression with preserved renal blood flow. Transplantation 1999;68: 1746-1753.
26. Morrisett JD, Abdel-Fattah G, Hoogeveen R, Mitchell E, Ballantyne CM, Pownall HJ, et al. Effects of sirolimus on plasma lipids, lipoprotein levels, and fatty acid metabolism in renal transplant patients. J Lipid Res 2002;43: 1170-1180.
27. Houde VP, Brûlé S, Festuccia WT, Blanchard PG, Bellmann K, Deshaies Y, Marette A. Chronic rapamycin treatment causes glucose intolerance and hyperlipidemia by upregulating hepatic gluconeogenesis and impairing lipid deposition in adipose tissue. Diabetes 2010;59: 1338-1348.
28. Tremblay F, Gagnon A, Veilleux A, Sorisky A, Marette A. Activation of the mammalian target of rapamycin pathway acutely inhibits insulin signaling to Akt and glucose transport in 3T3-L1 and human adipocytes. Endocrinology 2005;146: 1328-1337.
29. Morrisett JD, Abdel-Fattah G, Kahan BD. Sirolimus changes lipid concentrations and lipoprotein metabolism in kidney transplant recipients. Transplant Proc 2003; 35(suppl): 143S-150S.
30. Kurdi M, Booz GW. Three 4-letter words of hypertensionrelated cardiac hypertrophy: TRPC, mTOR, and HDAC. J Mol Cell Cardiol 2011;50: 964-971.
31. Soesanto W, Lin HY, Hu E, Lefler S, Litwin SE, Sena S, et al. Mammalian target of rapamycin is a critical regulator of cardiac hypertrophy in spontaneously hypertensive rats. Hypertension 2009;54: 1321-1327.
32. Romero F, Rodríguez-Iturbe B, Pons H, Parra G, Quiroz Y, Rincón J, Gonzá lez L. Mycophenolate mofetil treatment reduces cholesterol-induced atherosclerosis in the rabbit. Atherosclerosis 2000;152: 127-133.
33. Boesen EI, Williams DL, Pollock JS, Pollock DM. Immunosuppression with mycophenolate mofetil attenuates the development of hypertension and albuminuria in deoxycorticosterone acetate-salt hypertensive rats. Clin Exp Pharmacol Physiol 2010;37: 1016-1022.